Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Fareva Pilots New GMP Unit at Its Pau Site | Contract Pharma

What are you searching for?

Sign in
Breaking News

Fareva Pilots New GMP Unit at Its Pau Site

The company opened a new GMP Pilot Unit to produce liquid and lyophilized injectable forms.

By: Rachel Klemovitch

Assistant Editor

Fareva has opened a new GMP Pilot Unit at its Pau site to produce liquid and lyophilized injectable forms. With its new isolator, Fareva offers development services for formulation and aseptic filling of liquid and lyophilized forms. 

The pilot unit benefits from the full support of Pau site’s existing infrastructure, including Quality Assurance, EHS, Engineering, Logistics (procurement, cold chain), inspection (mirage), and packaging, as well as new capabilities. 

This new production capability supports development studies, clinical trial batch production, and even the manufacturing of small commercial batches (e.g., pediatric or orphan drugs).

The equipment complies with the latest requirements of the new Annex 1 for sterile products. It enables the manufacturing of biotech-derived medicines, such as monoclonal antibodies, mRNA in LNP form, proteins, peptides, recombinant proteins, and ADCs.

The isolator allows handling a broad spectrum of products, from small molecules classified OEB 1 to highly potent substances up to OEB 5.

This unit includes an aseptic preparation area for bulk formulation, which is filled into vials via an aseptic line connected under laminar flow to a 2m² lyophilizer, following Annex 1.

An autoclave is also available for products requiring terminal sterilization. Fareva Pau features an integrated cold chain system, meeting stringent temperature monitoring standards throughout every stage of the manufacturing cycle. 

This ensures optimal preservation conditions for sensitive products, including storage of Drug Substances (DS), maintaining formulations at required temperatures before filling, and preserving Drug Products (DP) until shipment.

New capabilities will support Phase 1 to Phase 3 studies and scale up to commercialization through Fareva’s industrial network (5 sterile production sites).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics